Companion animals are becoming a family and are increasing the demand for more sophisticated and effective treatments. Triviumvet is developing new treatments for the previously unmet needs of our cats and dogs.
Ireland-based Triviumvet’s Waterford is making a wave of veterinary medicine with breakthroughs in companion animal healthcare. Focused on addressing unmet clinical needs, the company is a pioneering treatment for chronic pet diseases. This is an area where effective solutions have long been short.
Innovation meets your purpose
Founded by the visionary Louise Grubb and Tom Brennan, Triviumvet’s product portfolio works to address chronic diseases with little or no treatment options for clinicians and owners. The company has since been struck by the market’s veterinary treatments and new animal medicines targeting conditions such as feline hypertrophic cardiomyopathy (HCM), neuropathic pain in dogs, stomach ulcers in dogs, and chronic kidney disease in pets, and other impressive conditions. We have developed a pipeline.
Triviumvet’s flagship product for cats represents a monumental breakthrough. This patented, delayed release, Sirolimus, offers the first-ever option for HCM, a debilitating disease that affects up to 15% of cats. The company has secured regulatory approval for U.S. products, empowered veterinarians to step in early, allowing them to potentially change the lives of countless cat patients.
A unique approach to veterinary development
What sets Triviumvet apart is its innovative approach.
Focus on unmet needs: We target diseases that lack effective treatment and ensure that we strive to address the most pressing challenges in veterinary care. Adopting advances in human medicine: By leveraging cutting-edge technologies from human medicine, Triviumvet brings new solutions to the veterinary department. Species-specific formulations: Therapeutics are tailored to the individual species to ensure optimal efficacy and safety. Holistic Health Solutions: Beyond treatments for specific conditions, Triviumvet develops treatments that enhance the overall quality of life of your pet, addressing age-related declines and chronic diseases.
These differentiators not only bridge the gaps in traditional veterinary care, but also set new standards for animal health innovation.
Global vision, local roots
Under the leadership of CEO Louise Grubb, Triviumvet combines a global perspective with local dedication. Triviumvet’s ability to bring products from concept to market is supported by a robust internal team and a network of external experts, including leading opinion leaders, contract research institutes, and contract manufacturing organizations. The manufacturing industry is outsourced, but quality and development remains under Triviumvet’s control.
This joint model ensures not only a rigorous development process but also strong approval from veterinary professionals and places the company’s products for widespread adoption at launch.
A promising future for veterinary medicine
With its innovative drug delivery systems, strict R&D processes and dedication to addressing unmet needs, Triviumvet is poised to revolutionize veterinary medicine. Grubb said: “Pets are considered families and this shift drives the demand for advanced healthcare solutions.”
Triviumvet is at the forefront of this transformation and offers treatments to meet the growing expectations of pet owners. Their efforts not only improve the health and life expectancy of pets, but also provide veterinarians with the tools they need to make a meaningful difference in their patients’ lives.
Triviumvet’s journey is a testament to the power of innovation and purpose-driven leadership. As they continue to break new ground, the company is solidifying its position as a leader in companion animal healthcare. This is a milestone worthy of recognition and celebration.
This article will also be featured in the 21st edition of Quarterly Publication.
Source link
